Kurzius Lawrence Erik has demonstrated a clear selling bias in recent transactions, particularly concentrated in McCormick & Company (MKC), according to SEC Form 4 filings. Over 27 reported trades across four companies—MKC, Cooper Companies (COO), Elanco Animal Health (ELAN), and Lamb Weston (LW)—Kurzius has sold approximately $19.9 million worth of shares while purchasing $10.5 million, with the bulk of activity in MKC. Recent transactions include multiple high-value sales, such as a $3.58 million disposal on February 12, 2026, and a $3.37 million sale on January 13, 2026, alongside smaller but consistent sales throughout late 2025. The pattern suggests a steady reduction in MKC holdings, with only minor purchases in COO ($165,000 on December 17, 2025) and ELAN ($213,000 on December 12, 2025) appearing as exceptions.
The data reveals that Kurzius’s trading in MKC has been particularly active since late 2025, with sales frequently accompanied by "M"-coded transactions, likely representing option exercises or other derivative-related activity. For instance, a $2.49 million transaction on February 3, 2025, coincided with a $3.84 million sale, reinforcing the trend of monetizing positions. While earlier filings show occasional acquisitions, such as a $2.35 million purchase in February 2025, the recent direction skews decisively toward divestment. The absence of material buying activity in the past year, combined with the scale of MKC sales, indicates a shift in Kurzius’s portfolio strategy, though the reasons remain undisclosed in the filings.
AI-assisted summary